The Evolving Brain Cancer Landscape
Brain and CNS cancers remain disproportionately lethal, ranking 12th in mortality despite being only 19th in prevalence. With cases and deaths projected to rise sharply by 2045, there is an urgent need for more effective therapeutic strategies.
With exclusive data from Beacon, this report contains insights into:
- Biomarkers: EGFR & HER2 are the most studied biomarkers, with trials mainly in phase 1 & 2
- Therapeutics: Small molecules lead late-stage development, due to blood-brain-barrier penetration
- Targets: B7-H3 & EGFRviii are key targets driving innovative drug development
- First Time Approvals: Six new therapies, including vorasidenib and tovorafenib, gained approval since 2021
You May Also Be Interested In…
Learn More About Oncology
What is Beacon Oncology?
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
